personalized neoantigen mRNA vaccine

Phase 1

personalized neoantigen mRNA vaccine is one of 31 therapeutic programs targeting Rhabdomyosarcoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

RhabdomyosarcomaRecruiting

RhabdomyosarcomaPhase 1

Recruiting

Competition

Competitive Landscape

36 competitors in Rhabdomyosarcoma

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

16 2

Verzenio

Eli Lilly

Approved

—3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 4

Camptosar

Pfizer

Phase 3

8 5

Oncovin

Eli Lilly

Phase 3

6 6

Adriamycin

Pfizer

Phase 3

6 7

Cosmegen

RRECORDATI GROUP

Phase 3

17 8

Ifex

BBaxter Healthcare Corporation

Phase 3

8 9

Vepesid

AAvyxa

Phase 3

7 10

Neupogen

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Rhabdomyosarcoma

NCT06932861

Clinical

Trials by Indication[1]

Rhabdomyosarcoma1 trial

Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

Recruiting·XXinxin Zhang·Phase 1·NCT06932861·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for personalized neoantigen mRNA vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for personalized neoantigen mRNA vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xinxin Zhang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: XXinxin Zhang

personalized neoantigen mRNA vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Rhabdomyosarcoma1 trial

References

Drug Info

Quick Facts

Related News